Get In Touch
Allegory Capital SA,
Rue du Sablon 2
1110 Morges
Switzerland
+41 21 561 34 97
contact-ch@allegory.capital
Work Inquiries
work@allegory.capital
+41 21 561 34 97
Back

Venture capital

A white marble box tied with a deep-green ribbon, sliced into bands, pulled apart by a ribbon knotted to a separate marble block: a closed deal unwound from outside.
  • Orsen Okami
  • Posted by Orsen Okami
October 20, 2026

Beijing Unwound a Closed $2 Billion Deal. Closing Certainty Is Now a Political Variable.

Beijing's order to unwind Meta's closed Manus deal shows closing certainty now depends on the founders' home state, so cross-border sellers must price political reversal into signing.

Read More
A black angular skyscraper in black and white, its hollow middle section glowing neon yellow
  • Orsen Okami
  • Posted by Orsen Okami
October 14, 2026

Megafunds Took 73% of the Money. The Single-Digit-Billion Exit Is Now an Orphan.

Five firms took 73% of new US venture capital in Q1 2026. Allegory Capital's portfolio model shows why the orphaned single-digit-billion exit rewards investors who diversify across vehicles.

Read More
A glowing chartreuse cube waits before seven receding stone gateways under a slate sky, a metaphor for a product users love facing the organisation's approval gates
  • Orsen Okami
  • Posted by Orsen Okami
October 6, 2026

Users Buy the Product. Organisations Buy the Company.

Product-market fit proves users want the product; procurement fit proves the organisation can buy the company, and in regulated Europe that second fit is an investable asset.

Read More
  • Orsen Okami
  • Posted by Orsen Okami
July 13, 2026

Why Regulated-Industry Startups Are Capturing Disproportionate Series B Capital in Europe: What the Investment Thesis Actually Requires

TLDR: Regulated-industry startups in healthtech, insurtech, legaltech, and compliance-tech are capturing an...

Read More
  • Orsen Okami
  • Posted by Orsen Okami
July 1, 2026

ONWARD Medical Skipped Swiss Funds, Found European Specialists, and Reached a Euronext IPO

An investor read: a 'no' from the wrong-mandate fund is information about fit, not a verdict on the company.

Read More
  • Orsen Okami
  • Posted by Orsen Okami
June 30, 2026

Investors Decide on Founders in the First Ninety Seconds, Not the Pitch Deck

From the other side of the table: what an early-stage investor is actually underwriting is the founder, not the slides.

Read More
  • Orsen Okami
  • Posted by Orsen Okami
June 26, 2026

A 25% Stake Can Be Worth Zero: How Liquidation Waterfalls Really Pay Out

Liquidation waterfalls pay senior preferred shareholders first, so a 25 per cent ownership stake can return nothing — ownership percentage anchors expectations that seniority quietly overrides at exit.

Read More
  • Orsen Okami
  • Posted by Orsen Okami
June 26, 2026

Where April 2025 Digital Health Capital Actually Went

April 2025's biggest digital-health cheques went to diagnostics, metabolic hardware, care-operations software, and fertility infrastructure. Where value compounds next.

Read More
  • Orsen Okami
  • Posted by Orsen Okami
June 25, 2026

AI Screens Deals 537× Faster, but Venture Fees Keep Climbing

An AI agent now screens early-stage deals 537 times faster than a human analyst, yet venture management fees keep rising — because the fee was never only the price of screening labour.

Read More
  • Orsen Okami
  • Posted by Orsen Okami
June 23, 2026

Venture Funds Stopped Returning Cash. LPs Rewrote the Scorecard Around DPI.

Distributions to paid-in has overtaken paper marks as the number limited partners trust, and the 2017 vintage shows even strong funds returning roughly a quarter of committed capital eight years in.

Read More